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Abstract
Background and Aims: With the availability of direct-acting
antiviral (DAA) therapy for hepatitis C virus (HCV) infection
and changing liver disease etiology for liver transplantation
(LT), data on the changes in LT recipient population in the
DAA era are scanty. Methods: The United Network for Organ
Sharing (UNOS) registry (01/2007 to 06/2018) was used to
develop a retrospective cohort of LT recipients for HCV, alco-
hol-associated liver disease (ALD), and non-alcoholic steato-
hepatitis (NASH). LT recipients in the DAA era (2013-2018)
were compared with those in the pre-DAA era (2007-2012)
era for recipient characteristics. Chi-square and analysis of
variance were the statistical tests used for categorical and con-
tinuous variables, respectively. Results: Of 40,309 LT recipi-
ents (21,110 HCV, 7586 NASH, and 11,713 ALD), the 21,790
in the DAA era (9432 HCV, 7240 ALD, and 5118 NASH) were
more likely to be older, female, obese, diabetic, have acute-on-
chronic liver failure with a higher model for end-stage liver
disease score, receive grafts with a lower donor risk index,
and have waited on the LT list for a shorter period compared
with their pre-DAA era counterparts. Specific to ALD, LT recip-
ients with alcohol hepatitis were more likely to be younger at
the time of LT. Of 9895 LT recipients with hepatocellular carci-
noma, recipients in the DAA era were observed to have a high-
er proportion of HCV (43% vs. 32%, p<0.001), a lower
proportion of ALD (9% vs. 12%, p<0.001), and no change
for NASH (13% vs. 13%, p=0.9) compared with the pre-DAA
era. Within the hepatocellular carcinoma population, LT recip-
ients in the DAA era were older, diabetic, and waited on the LT
list longer compared with their pre-DAA counterparts. Conclu-
sions: Along with changing liver disease etiology in the DAA
era, the LT recipient population demographics, comorbidities,
liver disease severity, and graft quality are changing. These
changes are relevant for future studies, immunosuppression,
and post-transplant follow-up.
Citation of this article: Xie C, Kuo YF, Singal AK. Changing
population of liver transplant recipients in the era of direct-act-
ing antiviral therapy. J Clin Transl Hepatol 2020;8(3):262–266.
doi: 10.14218/JCTH.2020.00032.
Introduction
Direct-acting antiviral (DAA) therapy has dramatically
impacted the landscape of hepatitis C virus (HCV) infection
treatment. Unlike interferon-based therapy, DAA treatment
has excellent safety and efficacy, with an over 95% HCV cure
rate.1 This change has resulted in a decrease in the require-
ment of liver transplantation (LT) for HCV. At the same time,
LT frequency for alcohol-associated liver disease (ALD) and
non-alcoholic steatohepatitis (NASH) cirrhosis has increased,
with ALD becoming the top indication for LT followed by NASH
cirrhosis.2–5 In contrast, HCV remains the leading indication
of LTamong patients with cirrhosis complicated by hepatocel-
lular carcinoma (HCC).5 However, the data on changes in the
DAA era study population is scanty compared to the era prior
to the availability of DAA.
Methods
Study population and definitions
The United Network for Organ Sharing (UNOS) database (01/
2007 to 06/2018) was stratified for LT recipients in the pre-
DAA (2007-2012) and DAA (2013-18) eras. The study
population included LT recipients with ALD, NASH, and HCV.
Patients who received transplants for HCC and one of these
three etiologies were included. In the database, UNOS codes
characterized liver disease etiologies and HCC. For each LT
recipient, the model for end-stage liver disease (MELD) score
and donor risk index (DRI) were calculated using the standard
formulae based on specific recipient and donor variables,
respectively. Organ failure and acute-on-chronic liver failure
(ACLF) were defined using the European Association for the
Study of Chronic Liver Failure consortium criteria.6
Data analyses
Etiology-specific baseline characteristics of LT recipients were
compared for the pre-DAA era versus the DAA era. These
characteristics were also compared for recipients with and
without HCC. Chi-square and analysis of variance statistical
tests were used for comparison of categorical and continuous
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A total of 40,409 LT (21,790 in the DAA era) were performed
between Jan 2007 and June 2018. Of these, 21,110 LT (9432
in the DAA era) were performed for HCV, 11,713 (7240 in the
DAA era) for ALD, and 7586 (5118 in the DAA era) for NASH
(Table 1). A total of 267 LT (206 in the DAA era) among recip-
ients with ALD were performed because of a primary indica-
tion of alcoholic hepatitis (AH), with a higher proportion in the
DAA era versus the pre-DAA era (2.9% vs. 1.4%, p<0.001).
Overall, about 25% of LT (n=9975) were performed for liver
disease complicated by HCC, with no significant differences
between DAA and pre-DAA eras (p=0.75). Among the HCC LT
recipients, 7786 LT (4008 in the DAA era) were performed for
HCV, 1151 (629 in the DAA era) for ALD, and 958 (648 in the
DAA era) for NASH (Table 2). Etiology-specific change on con-
comitant HCC in the DAA era showed a significant increase for
HCV (43% vs. 32%, p<0.001), decrease for ALD (9% vs.
12%, p<0.001), and no change for NASH (13% vs. 13%,
p=0.9).
Baseline characteristics of LT recipients in the DAA era
versus pre-DAA era
Demographics: Overall, in the DAA era, as compared to the
pre-DAA era, LT recipients were older (57 vs. 55 years,
p<0.001). This was more apparent for HCV (58 vs. 55
years, p<0.001) and NASH (60 vs. 59 years, p<0.001)
cases. However, LT recipients with ALD were younger in the
DAA era (53 vs. 55 years, p<0.001). Similarly, more females
received LT in the DAA era (30% vs. 27%, p<0.001). These
female LTs were mainly contributed by ALD (25% vs. 22%,
p=0.002), with no gender differences for HCV- and NASH-
related transplants. There were no racial differences
between the two eras. However, in the DAA era, more minor-
ities (Blacks, Hispanics, and other races) received LT because
of NASH (25% vs. 22%, p<0.001) and ALD (31% vs. 29%,
p=0.004) indications.
Among HCC transplants: Within the HCC transplant
subgroup, recipients were older (61 vs. 58 years, p<0.001).
There were no gender differences for any of the etiologies.
Although there was no overall racial difference, in the DAA
era, HCV-related LTs were more often performed for minor-
ities (41% vs. 40%, p<0.001).
Comorbidities: Patients in the DAA era were more often
obese (41% vs. 39%, p<0.001), diabetic (31% vs. 28%,
p<0.001), and in need of dialysis (18% vs. 13%, p<0.001)
versus the pre-DAA era. In the DAA era, the proportion of
obese recipients decreased for NASH (60% vs. 65%,
p<0.001), without any change for the other two indicators.
In contrast, in the DAA era, diabetes was a more frequent
comorbidity for HCV (25% vs. 24%, p<0.02), less frequent
comorbidity for ALD (20% vs. 24%, p<0.001), and, although
there appeared to be an increasing trend, there was no stat-
istical difference in NASH (59% vs. 57%, p=0.22). The use of
dialysis was more frequent in the DAA era for all etiologies
(14% vs. 11% for HCV, 19% vs. 14% in NASH, and 23%
vs. 17% in ALD, p<0.001).
Among HCC transplants: The frequency of obesity was
similar for all etiologies. However, diabetes (34% vs. 29%,
p<0.001) and use of dialysis (3.4% vs. 2.5%, p=0.012)
were more frequent in the DAA era versus the pre-DAA era,
especially among LT for HCV that were HCC-related.
Transplant characteristics: The mean MELD score at LT
was higher in the DAA era (21.2 vs. 21, p<0.001). This
change was mainly contributed by ALD (25 vs. 23,
p<0.001). There was no statistical difference in NASH (22
vs. 22, p=0.87) and a decrease in MELD among HCV-
related (18 vs. 20, p<0.001) LT. Similarly, LT was more
often performed for ACLF in the DAA era (40% vs. 36%,
p<0.001). The etiology-specific proportion of ACLF showed
an increase for ALD (51% vs 43%, p<0.001) and NASH
(41% vs. 38%, p=0.003) without there being a significant
difference for HCV (31% vs. 32%, p=0.1). Within ALD etiol-
ogy, as compared to the pre-DAA era, the proportion of LT for
ACLF 2 and 3 (severe ACLF) and for AH was more frequent in
the DAA era (36% vs. 26% and 2.9% vs. 1.4%, respectively,
p<0.001). Overall, the mean wait time on the LT list was 2
weeks shorter in the DAA era (252 vs. 266 days, p=0.002).
The wait time was primarily contributed by ALD etiology (157
vs. 200 days, p<0.001). In the DAA era, LT recipients with
NASH (342 vs. 306 days, p<0.001) and HCV (218 vs. 199
days, p<0.03) waited longer. Overall, a better quality graft
was used in the DAA era with a DRI mean lower than in the
pre-DAA era (1.56 vs. 1.57, p<0.001). This was observed for
all the etiologies (1.53 vs. 1.55 for HCV, 1.59 vs. 1.61 for
NASH, and 1.57 vs. 1.61 for ALD, p<0.02).
Among HCC transplants: The mean MELD score was
lower in the DAA era (11 vs. 12, p<0.001), mainly for LT
recipients with HCV-related HCC (10.7 vs. 11.5, p<0.001).
There were not mean differences for the other two indicators.
In the DAA era, LT recipients with HCC waited a month longer
(423 vs. 390 days, p<0.008), mainly for HCV (426 vs. 386
days, p<0.004) and NASH (371 vs. 292 days, p<0.01) cases.
There were no differences for ALD cases (459 vs. 484 days,
p=0.53). In the DAA era, although graft quality was better,
with a mean DRI lower for all etiologies, the results were not
significant (1.55 vs. 1.56, p=0.19), probably due to a small
sample size compared to when analyses were performed for
all LT.
Discussion
The main findings of this UNOS database analysis are that the
recipients of LT in the DAA era, as compared to the pre-DAA
era, are more likely to be older females, have obesity and
diabetes as comorbidities, have higher MELD with more
frequent transplants for ACLF and organ failure, and receive
better grafts with a shorter wait time on the LT list. Although
ACLF and multiple organ failure are associated with high
mortality and poor prognosis without LT, the disease severity
may not be fully reflected in the MELD-Na score. With the
advancement of intensive care and organ failure supportive
care, many studies recommend early recognition and trans-
plant evaluation for patients with ACLF and advocate for
additional priority on the waitlist.7–9 Specific to HCV, the LT
for HCC increased in the DAA era, while a decreased rate for
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HCC-related LTwas observed for ALD and NASH.Within the HCC
population, LT recipients in the DAA era were more likely to be
older, diabetic, require dialysis, and wait longer on the LT list.
This is consistent with a recent publication that indicated DAA
treatment prior to LTwas associated with a longer waitlist time.
However, DAA improved the outcome and mitigated LT need in
low MELD recipients.10 Meanwhile, graft survival outcomes also
improved among HCV-positive recipients in the DAA era.11
The increasing age of LT recipients may be due to increas-
ing longevity and better management of patients delaying the
need for LT.12 However, LT recipients for ALD were younger in
the DAA era, likely due to the increased frequency of high-risk
drinking in this age group, with the development of ACLF and
organ failure.13 A significant proportion of this change in the
ALD population is due to increasing LT for AH, as observed in
this study and in alignment with earlier reports.13,14 These
changes, along with increasing hospitalizations observed in
other studies on ACLF related to NASH, accounted for
increased frequency of LT for ACLF and organ failure with a
higher MELD score.3 Despite the LT population in the DAA era
becoming more obese and diabetic due to an increasing prev-
alence of these comorbidities in the population, a more rigor-
ous evaluation of LT candidates for NASH cirrhosis probably
explains lower rates of obesity in this etiology in the DAA era.
Observation of increasing LT for HCC related to HCV cirrhosis
in the DAA era is similar to the earlier observation of HCV still
being the leading indication for HCC-related LT in the USA.5
Better quality grafts are used in the DAA era compared to the
pre-DAA era, to optimize post-transplant outcomes given that
the recipient age and disease severity have increased in the
DAA era, and these factors are negatively associated with
post-transplant survival.15
In conclusion, the changes in the LT recipient population in
the DAA era, as a result of changing liver disease etiology for
LT, are relevant for designing future studies for this popula-
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